Showing results (1-10 of 4) with videos related to
Sort By:
Pageof 1
Journal of the Chinese Medical Association : JCMA|July 19, 2023
Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological responseChih-Hsuan Luan, Pin-Shuo Su, Chi-Jen Chu, et al.Journal of the Chinese Medical Association : JCMA|November 11, 2021
Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosisPin-Shuo Su, Sih-Hsien Wu, Chi-Jen Chu, et al.Journal of the Chinese Medical Association : JCMA|April 19, 2021
Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antiviralsPin-Shuo Su, Chien-Wei Su, Sih-Hsien Wu, et al.Journal of the Chinese Medical Association : JCMA|January 5, 2024
Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patientsChih-Hsuan Luan, Pin-Shuo Su, Chi-Jen Chu, et al.Pageof 1